- BRSF is modernizing brain diagnostics with cost-effective, disposable solutions that help minimize risk of spreading disease
- AI-assisted analysis allows for processing of relevant data in real time at high speed for early diagnosis, higher rate of successful treatments
Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics by employing cutting-edge tech to bridge the widening gap in access to quality care. BRSF is achieving this through cost-effective and disposable substitutes to existing solutions that improve patients’ access to neurological care.
Currently, BRSF is in phase two of a three-phase plan for development. Phase one of development occurred in 2018–2019 with the inception of portable, clinical-grade, easy-to-use neurological devices. The company’s two FDA-cleared products — NeuroCap(TM) and NeuroEEG(TM) — are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific. Additional devices currently under development address routine EEG, pediatric EEG, long-term monitoring, AI and telemedicine.
The disposable and cost-effective NeuroCap could end up being a viable tool in the treatment of those infected with COVID-19. Over 80% of hospitalized patients from the pandemic have been displaying neurological symptoms (
https://ibn.fm/nmbSd). The disposable aspect of the NeuroCap is key in the treatment as reusable EEG electrodes have the potential for putting patients in further risk (
https://ibn.fm/K4pg4).
Phase two of development, which is currently ongoing, is the creation of a cloud-based, secure infrastructure to transmit patient data between patients and teleneurologists. The demand for neurological services is growing. According to the American Academy of Neurology, the demand for neurologists is outpacing the supply. It is estimated that by 2023, the United States will be short anywhere from 20,600 to 39,100 specialists, including neurologists (
https://ibn.fm/HpdcT), which means patients will likely end up waiting to see a neurologist. Creating a cloud-based infrastructure could allow patients to access this vital care.
Phase three (planned for 2021–2022) focuses on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.
Brain Scientific is developing several new products for the AI market, incuding the following:
- Brain E-Tatoo is a subcutaneous, minimally invasive, implantable EEG electrode designed for long-term monitoring to detect epileptic seizures.
- Brain AI is not one product but rather a database of biomarkers that work to develop algorithms to detect abnormal activity.
AI-assisted analysis is vital in moving forward for better care and treatment for patients. A massive amount of data and published studies has been created as the healthcare community discovers new medicines, new applications of medication, new precautions and new approaches to patient care. More data has been produced than a human can process. AI-assisted analysis allows for the processing of relevant data in real time at high speed to allow for the early diagnosis and probabilistic success rates for various treatments. This approach, one in which Brain Scientific is leading the way, provides a tool for the neurologist to provide optimal care to each and every patient.
For more information, visit the company’s website at
www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at
https://ibn.fm/BRSF
